Affinity Biosensors

Antimicrobial resistance (AMR) is one of the greatest medical challenges of our time, and Affinity Biosensors is on a mission to deliver the fastest, most actionable diagnostic solutions to save time, save lives, and reduce costs in critical care. Our team leverages deep expertise in mass measurement at femtogram levels to transform how healthcare providers identify, manage, and combat infectious diseases. LifeScale: Faster, More Accurate AST Our FDA-cleared LifeScale AST system redefines antibiotic susceptibility testing by delivering near–real-time insights (in ~4.5 hours) directly from positive blood cultures. Unlike traditional colony-based methods, LifeScale employs a microfluidic sensor that measures individual bacteria with femtogram-level precision. This technology empowers clinicians to see delayed-growth phenotypes, guiding more targeted antibiotic therapy and supporting robust antimicrobial stewardship. Advancing Next-Generation Diagnostics Building on LifeScale's success, we are now expanding into rapid antifungal susceptibility testing—a vital step in addressing urgent threats like Candida auris. By continuing to innovate and refine our mass-sensing approach, we aim to give hospitals the tools they need to outpace evolving pathogens and protect precious antibiotic resources. Join Us in the Fight Against AMR At Affinity Biosensors, our vision is to ensure that every minute counts when it comes to diagnosing and treating life-threatening infections. By providing clinicians with timely, accurate data, we help reduce treatment durations, contain costs, and ultimately improve patient outcomes. Learn more about our mission and technology at affinitybio.com.

• Employees 30
• Founded 2006
• Annual Revenue $70000000
• Total Funding $47675451